NBIX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Neurocrine Biosciences Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 166.8 USD
-5.1% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 14.4% above the Trend Line and sits at 69.8% of its 52-week range. The latest completed week returned -5.1%, after a -4.3% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bullish with 45/100 conviction, while the latest news-sentiment score is 60/100.

Setup score 61 out of 100
Latest Close 166.8 USD 31 Jul 2026
1W Return -5.1% latest completed week
4W Return -4.3% short-term follow-through
12W Return 9.6% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 1.7x vs 13-week average
What is working
  • The trend backdrop is active with a 9-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 17 reversal markers appear in the recent smart-money tape.
  • The latest week was a sharp negative move.
  • Latest weekly return ranks in the weaker part of its sector group.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.1% Latest completed week; four-week move -4.3%. Indicator stack 65/71 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 56.09% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 45/100 conviction; expected move 6.4%. News sentiment 60/100 56 relevant articles in the latest sentiment read. Event risk 30 Jul Latest stored earnings date was 30 Jul 2026.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.4% above the Trend Line and sits at 69.8% of its 52-week range. The latest completed week returned -5.1%, after a -4.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8912-week average 0.54

12-week confirmation

Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership7/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.89Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1717 reversal markers

No recent accumulation markers. 17 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -4.3% over four weeks, 9.6% over 12 weeks, and 29.4% over one year. The current trend has remained active for 9 consecutive weeks.

Performance by holding period

1W-5.1%
4W-4.3%
12W9.6%
26W22.6%
52W29.4%
Active trend streak9 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.15Latest activity-pressure read.
Pressure change2.2%Four-week change in activity pressure.
Leadership5.99Latest relative-leadership reading.
RS change-18.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value13/100Relative valuation strength. Underlying universe rank 88; rank 1 is best.
Quality95/100Profitability and accounting quality. Underlying universe rank 6; rank 1 is best.
Momentum77/100Medium-term price momentum. Underlying universe rank 24; rank 1 is best.
Growth92/100Revenue and earnings growth. Underlying universe rank 9; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework53/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
26.4x
Price divided by trailing earnings.
Price / sales
5.7x
Market value relative to trailing revenue.
EV / EBITDA
18.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
5.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.2%
Gross profit retained from each unit of revenue.
Operating margin
29.8%
Operating profit retained from revenue.
Free-cash-flow margin
29.0%
Free cash flow generated from revenue.
Return on invested capital
18.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
28.6%
Latest one-year revenue growth.
EPS growth
118.6%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
58.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.3%
Net share repurchases relative to market value.
Shareholder yield
-0.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

NBIX shows bullish options pressure with a 45/100 conviction score, put-call volume ratio of 0.46, expected move of 6.4%, and Sharemaestro trend signal active.

Conviction45/100
Expected move6.4%
Put/call volume0.46
Pressure39
Speculation42
Volatility42
Trend agreement57
Open options detail
Insider activity7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment60/100

Weighted news tone is neutral across 56 relevant articles.

28 positive · 26 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings30 JulLatest stored earnings date was 30 Jul 2026.
Options expected move6.4%Nearest-chain priced movement where available.
52-week drawdown-10.4%Distance below the 52-week high.
13-week volatility5.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+15.5%Week of 8 May.
Worst week-12.1%Week of 13 Feb.
Latest week-5.1%Week of 31 Jul.

Shape of recent returns

Strong gains3
Modest gains13
Flat weeks0
Modest losses7
Sharp losses3
Recent vol5.1%13-week weekly-return volatility.
Base vol4.2%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew3.6% / -2.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape63/100

Trend, activity pressure, participation, and risk combine to a 63/100 tape read.

 Indicator analysis67/100

Latest 12-week confirmation: trend 9/12, activity pressure 12/12, relative leadership 7/12.

Activity pressure 0.89; 17 reversal markers Next-Week ExpectancyPositive 56.09%

Next-week expectancy is positive with a 56.09% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 74; Small Cap Core rank 95 SVQF53/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 338.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options60/100

NBIX shows bullish options pressure with a 45/100 conviction score, put-call volume ratio of 0.46, expected move of 6.4%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 6.4% Sentiment60/100

Weighted news tone is neutral across 56 relevant articles.

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand Insiders7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

 Earnings30 Jul

Latest stored earnings date was 30 Jul 2026.

 Research flow2 items

2 recent research articles and 0 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026166.8 USD-5.1%145.8 USD132.2 USD1.155.9910.2MOn
24 Jul 2026175.8 USD2.9%144.9 USD131.8 USD1.1512.385.7MOn
17 Jul 2026170.9 USD-3.5%143.9 USD131.3 USD1.207.725.3MOn
10 Jul 2026177.1 USD1.6%143.1 USD130.9 USD1.217.095.3MOn
3 Jul 2026174.3 USD3.4%142.3 USD130.3 USD1.137.304.6MOn
26 Jun 2026168.5 USD6.5%141.6 USD129.8 USD1.224.766.2MOn
19 Jun 2026158.3 USD-0.9%141.1 USD129.3 USD1.13-5.965.9MOn
12 Jun 2026159.8 USD-2.5%140.5 USD128.9 USD1.17-2.774.8MOn
5 Jun 2026163.9 USD3.5%140.0 USD128.5 USD1.271.906.6MOn
29 May 2026158.3 USD1.0%139.7 USD128.1 USD1.26-6.044.7MOff
22 May 2026156.7 USD-1.1%139.2 USD127.7 USD1.04-4.495.5MOff
15 May 2026158.4 USD4.1%138.7 USD127.2 USD0.66-2.426.7MOff
8 May 2026152.2 USD15.5%138.1 USD126.8 USD0.35-6.598.3MOff
1 May 2026131.8 USD3.2%137.6 USD126.5 USD-0.12-14.885.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.